Human medicines European public assessment report (EPAR): Kanjinti, trastuzumab, Date of authorisation: 16/05/2018, Revision: 13, Status: Authorised

Withdrawn application: Kaftrio, 01/09/2026

Human medicines European public assessment report (EPAR): Prevenar 20 (previously Apexxnar), pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed), Date of authorisation: 14/02/2022, Revision: 13, Status: Authorised

Pilot phase for the revised pre-submission interactions: Annex to request for rapporteurship

Human medicines European public assessment report (EPAR): Afqlir, aflibercept, Date of authorisation: 13/11/2024, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Nordimet, methotrexate, Date of authorisation: 18/08/2016, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Bimervax, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 30/03/2023, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Enhertu, trastuzumab deruxtecan, Date of authorisation: 18/01/2021, Revision: 23, Status: Authorised

Human medicines European public assessment report (EPAR): Degarelix Accord, degarelix, Date of authorisation: 29/09/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Skyclarys, omaveloxolone, Date of authorisation: 09/02/2024, Revision: 11, Status: Authorised